Skip to main content
Figure 2 | BMC Cancer

Figure 2

From: Is [F-18]-fluorodeoxy-D-glucose positron emission tomography of value in the management of patients with craniofacial bone sarcomas undergoing neo-adjuvant treatment?

Figure 2

Assessment of response to preoperative chemotherapy; determined by 18 FDG PET/CT and MRI scanning. PET/CT response was assessed according to EORTC guidelines, SMD = 2, PMR = 8, CMR = 2 after 2–4 cycles; SMD = 3, PMR = 7, CMR = 2 preoperatively. MRI was assessed according to RECIST criteria, SD = 10, PR = 2 both after 2–4 cycles and preoperatively.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us